Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2007-01-02
2007-01-02
Borin, Michael (Department: 1631)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C514S002600, C514S012200
Reexamination Certificate
active
10181102
ABSTRACT:
Novel exendin peptide compounds are provided.
REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5424286 (1995-06-01), Eng
patent: 5512549 (1996-04-01), Chen
patent: 5545618 (1996-08-01), Buckley
patent: 5574008 (1996-11-01), Johnson
patent: 5686511 (1997-11-01), Bobo
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: WO 9011296 (1990-10-01), None
patent: WO 9111457 (1991-08-01), None
patent: WO 9318786 (1992-09-01), None
patent: WO 9325579 (1993-12-01), None
patent: WO 9805351 (1998-02-01), None
patent: WO 9819698 (1998-05-01), None
patent: WO 9830231 (1998-07-01), None
patent: WO 9907404 (1999-02-01), None
Atlas of Protein Sequence and Structure, vol. 5. Natl. Biomedical Research Foundation, Washington, p. 96, 1972.
Adelhorst, K., et al., “Structure-activity Studies of Glucagon-like Peptide-1 (GLP-1),”J. Biol. Chem., 269(9):6275-8 (1994).
Bartlett, et al., “Inhibition of Chymotryspin by Phosphonate and Phosphonamidate Peptide Analogs,”Bioorg. Chem., 14:356-377 (1986).
Bhavsar, “Inhibition of Gastic Emptying and of Food Intake Appear to Be Independently Controlled in Rodents,”Soc. Neurosci. Abst., 21:460 (188.8)(1995).
Cohen, et al.,The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation (1989).
D'Alessio, et al., “Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest., 97:133-38 (1996).
Eissele, et al., “Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide,”Life Sci., 55:629-34 (1994).
Eng, et al., “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom,”J. Biol. Chem., 267:7402-05 (1992).
Eng, et al., “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,”J. Biol. Chem., 265:20259-62 (1990).
Fehmann, et al., “Stable Expression of the Rat GLP-I Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39),”Peptides, 15(3):453-6 (1994).
Ferguson, et al., “Cell-Surface Anchoring of Proteins Via Clycosylphosphatidylinositol Structures,”Annu. Rev. Biochem., 57:285-320 (1988).
Goke, et al., “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells,”J. Biol. Chem., 268:19650-55 (1993).
Goldstone, et al., “Leptin Interacts with Glucagon-like Peptide-1 Neurons to Reduce Food Intake and Body Weight in Rodents,”FEBS Letters,415:134-138 (1997).
Halaas, J.L., et al., “Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene,”Science, 269:543-546 (1995).
Kodama, J., et al., “Effect of Captopril on Glucose Concentration Possible Role of Augmented Postprandial Forearm Blood Flow,”Diabetes Care, 13(11):1109-1111 (1990).
Kolligs, et al., “Reduction of the Incretin Effect in Rats by the Glucagon-like Peptide-1 Receptor Antagonist Exendin (9-39) Amide,”Diabetes, 44:16-19 (1995).
Leibel, R.L., et al., “Changes in Energy Expenditure Resulting from Altered Body Weight,”New England Journal of Medicine, 332(10):621-628 (1995).
Lithell, et al., “Insulin Sensitivity in Newly Detected Hypertensive Patients: Influence of Captopril and Other Antihypertensive Agents on Insulin Sensitivity and Related Biological Parameters,”J. Cardiovasc. Pharmacol., 15 (Supp 5):S46-S52 (1990).
Malhotra, et al., “Exendin-4, a New Peptide fromHeloderma suspectumVenom, Potentiates Cholecystokinin-induced Amylase Release from Rat Pancreatic Acini,”Regulatory Peptides, 41:149-56 (1992).
Montrose-Rafizadeh, et al., “Structure-function Analysis of Exendin-4/GLP-1 Analogs,”Diabetes, 45 (Suppl. 2):152A (1996).
Navarro, M. et al., “Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake,”Journal of Neurochemistry, 67:1982-1991 (1996).
Ørskov, et al., “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable,”Diabetes, 42:658-61 (1993).
Pelleymounter, et al., “Effects of the Obese Gene Product on Body Weight Regulation in ob/ob Mice,”Science, 269:540-543 (1995).
Raufman, et al., “Trucated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas,”J. Biol.Chem., 267:21432-37 (1992).
Raufman, et al., “Exendin-3, a Novel Peptide fromHeloderma horridumVenom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas,”J. Biol. Chem., 266:2897-902 (1991).
Schepp, et al., “Exendin-4 and exendin-(9-39)NH2: Agonist and Antagonist, Respectively, at the Rat Parietal Cell Receptor for Glucagon-like Peptide-1-(7-36)NH2,”Eur. J. Pharm., 269:183-91 (1994).
Schjoldager, et al., “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucogon, Inhibit Gastric Acid Secretion in Humans,”Dig. Dis. Sci., 34(5):703-8 (1989).
Singh, et al., “Use of125I-[Y39]Exendin-4 to Characterize Exendin Receptors on Dispersed Pancreatic Acini and Gastic Chief Cells from Guinea Pig,”Regul. Pept., 53:47-59 (1994).
Thorens, “Expression Cloning of the Pancreatic B Cell Receptor for the Gluco-Incretin Hormone Glucagon-like Peptide 1,”Proc. Natl. Acad. Sci. USA, 89:8641-45 (1992).
Thorens, et al., “Cloning and Functional Expression of the Human Islet GLP-1 Receptor,”Diabetes, 42(11):1678-82 (1993).
Turton, et al., “A Role for Glucagon-Like Peptide-1 in the Central Regulation of Feeding,”Nature, 379:69-72 (1996).
Veale, P.R., et al., “The Presence of Islet Amyloid Polypeptide/Calcitonin Gen-Related Peptide/Salmon Calcitonin Binding Sites in the Rat Nucleus Accumbens,”Eurpean Journal of Pharmacology, 262:133-141 (1994).
Wang, et al., “Glucagon-like Peptide-1 Is a Physiological Incretin in Rat,”J. Clin. Invest., 95:417-21 (1995).
Watson, N., et al., “Effects of Captopril on Glucose Tolerance in Elderly Patients with Congestive Cardiac Failure,”Current Medical Research and Opinion, 12(6):374-378 (1991).
Wettergren, et al., “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,”Dig. Dis. Sci., 38(4):665-73 (1993).
Willms, et al., “Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liguid Test Mel: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients,”J. Clin. Endocrinol. Metab., 81(1):327-32 (1996).
Young, et al.,Program and Abstracts, 10thInternational Congress of EndocrinologyJun. 12-15, 1996, San Francisco, p. 419 (P2-58).
Beeley Nigel Robert Arnold
Prickett Kathryn Susan
Amylin Pharmaceuticals Inc.
Borin Michael
LandOfFree
Exendin agonist compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Exendin agonist compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exendin agonist compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3784816